Triple-negative breast cancer trials in Japan
24 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleA Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- Where
- Akita, Bunkyo, Fukuoka, Fukushima, Hidaka, Hiroshima, Isehara, Kagoshima, Kahoku-gun, Kashiwa, Kawasaki, Koto, Kyoto, Matsuyama, Minato, Nagoya, Naha, Okayama, Osaka, Sagamihara, Sapporo, Shinagawa, Shinjuku, Suita, Tsu, Yokohama
- Age
- 18 years and over
- People
- 1,000 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06841354 · EU 2024-516834-36-00 - Phase 3Taking peopleA Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Where
- Akita, Chiba, Chūō, Fukushima, Hirakata, Hiroshima, Kahoku-gun, Kumamoto, Kyoto, Matsuyama, Minato, Nagoya, Naha, Okinawa, Osaka, Sakai, Sapporo, Shinagawa, Suita, Sunto-gun, Tsu, Yokohama
- Age
- 18 years and over
- People
- 2,400 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06966700 · EU 2024-520190-12-00 - Phase 3Taking peopleSacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- Where
- Bunkyo, Chūō, Fukushima, Gifu, Hidaka, Hiroshima, Isehara, Kagoshima, Kashiwa, Kawasaki, Koto, Kumamoto, Kyoto, Nagoya, Okayama, Osaka, Ōta, Sagamihara, Sapporo, Sendai, Shinagawa, Shinjuku, Suita, Tsu, Yokohama
- Age
- 18 years and over
- People
- 1,530 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06393374 · EU 2023-504962-52-00 - Phase 1/2Taking peopleRinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Where
- Akashi, Fukushima, Hidaka, Koto, Nagaizumi-chō, Ōta, Sapporo, Shinjuku-ku, Yamagata
- Age
- 18 years and over
- People
- 952 worldwide
- Run by
- Genmab
See details and how to joinNCT05579366 - Phase 3Taking peopleStudy of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- Where
- Aichi, Chiba, Sapporo, Tokyo
- Age
- 18 years and over
- People
- 1,514 worldwide
- Run by
- Gilead Sciences
See details and how to joinNCT05633654 · EU 2024-512279-10-00 - Phase 1Taking peopleA Study of Sofe-M in Participants With Selected Advanced Solid Tumors
- Where
- Shizuoka, Tokyo
- Age
- 18 years and over
- People
- 575 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06400472 · EU 2024-511238-11-00 - Phase 1Taking peopleA Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Where
- Chūōku, Kashiwa, Chiba, Kōtō City, Nagoya
- Age
- 18 years and over
- People
- 460 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06465069 · EU 2024-512927-36-00 - Phase 3Taking peopleROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
- Where
- Bunkyō City, Chiba, Fukushima, Gifu, Hidaka, Hiroshima, Kagoshima, Kōtoku, Kumamoto, Kyoto, Matsuyama, Nagaizumi-chō, Nagoya, Osaka, Sakai, Sendai, Shinjuku-Ku, Tsu
- Age
- 18 years and over
- People
- 558 worldwide
- Run by
- BioNTech SE
See details and how to joinNCT07173751 · EU 2025-521884-12-00 - Phase 1/2Taking peopleSMP-3124LP in Adults With Advanced Solid Tumors
- Where
- Kashiwa-shi, Kyoto
- Age
- 18 years and over
- People
- 120 worldwide
- Run by
- Sumitomo Pharma America, Inc.
See details and how to joinNCT06526819 - Phase 1Taking peopleStudy to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
- Where
- Chuo-Ku, Kashiwa-shi, Koto-ku, Kyoto, Nagoya, Sunto-gun
- Age
- 18 years and over
- People
- 325 worldwide
- Run by
- AbbVie
See details and how to joinNCT06084481 · EU 2023-506227-29-00 - Phase 1Taking peopleA Study of [68Ga]Ga-DWJ155 in Adult Patients With Solid Tumors
- Where
- Kyoto
- Age
- 18 years and over
- People
- 66 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07801508 - Phase 1/2Taking peopleA Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
- Where
- Chūōku, Kashiwa
- Age
- 18 years and over
- People
- 120 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07115043 - Phase 3Taking peopleA Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
- Where
- Akashi-shi, Bunkyō City, Chiba, Chūōku, Fukuoka, Fukushima, Gifu, Hidaka-shi, Hiroshima, Isehara-shi, Kamogawa-shi, Kashiwa, Kitaadachi-gun, Kōtoku, Kumamoto, Kurume-shi, Matsuyama, Nagoya, Niigata, Nishinomiya-shi, Okayama, Osaka, Osakasayama-shi, Ota-shi, Sapporo, Sendai, Shinagawa-ku, Shinjuku-ku, Tsu, Tsukuba, Yokohama
- Age
- 18 years and over
- People
- 625 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06103864 - Phase 1Taking peopleEvaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Where
- Chūōku
- Age
- 18 years and over
- People
- 540 worldwide
- Run by
- SystImmune Inc.
See details and how to joinNCT05983432 - Phase 1Taking peoplePhase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors
- Where
- Chuo Ku
- Age
- 18 years and over
- People
- 66 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07630961 - Phase 1/2Taking peopleA Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
- Where
- Kashiwa
- Age
- 18 years and over
- People
- 1,109 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT04895709 - Phase 2/3Taking peopleA Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
- Where
- Bunkyo-ku, Chiba, Chuo-ku, Fukuoka, Fukushima, Hidaka, Hiroshima, Ina-machi, Isehara, Kagoshima, Kanazawa, Koto, Kyoto, Matsuyama, Nagoya, Okayama, Osaka, Otashi, Sapporo, Sendai, Shinagawa, Shinjuku-ku, Suita, Tsu, Yokohama
- Age
- 18 years and over
- People
- 600 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06926868 · EU 2024-519871-24-00 - Phase 1Taking peopleA Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- Where
- Kashiwa, Nagaizumi-chō
- Age
- 18 years and over
- People
- 714 worldwide
- Run by
- Seagen, a wholly owned subsidiary of Pfizer
See details and how to joinNCT05208762 · EU 2023-506604-18-00 - Phase 2Taking peoplePembrolizumab + Paclitaxel +/- Bevacizumab for Triple-negative Breast Cancer
- Where
- Akashi-shi, Gifu, Hiroshima, Kashiwa-shi, Koto-Ku, Nagoya, Okayama, Osaka, Sakai-shi, Sapporo, Shinagawa-Ku
- Age
- 18 years and over
- People
- 24
- Run by
- Yukinori Ozaki
See details and how to joinNCT06976944 - Phase 1Taking peopleStudy to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
- Where
- Chuo-ku, Hirakata-shi, Kashiwa-shi, Kobe, Nagoya, Sunto-gun, Wakayama
- Age
- 18 years and over
- People
- 694 worldwide
- Run by
- AbbVie
See details and how to joinNCT05005403 - Phase 1Taking peopleA Study of LY4175408 in Participants With Advanced Cancer
- Where
- Kyoto, Tokyo
- Age
- 18 years and over
- People
- 240 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07046923 · EU 2025-521916-20-00 - Phase 1/2Taking peopleA Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
- Where
- Chuo Ku, Koto-Ku
- Age
- 18 years and over
- People
- 182 worldwide
- Run by
- Eisai Inc.
See details and how to joinNCT04300556 · EU 2023-506868-14-00 - Phase 2Taking peopleNovel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer
- Where
- Gifu, Okayama, Tokyo
- Age
- 18 years and over
- People
- 23
- Run by
- Okayama University
See details and how to joinNCT05485766 - Phase 2Taking peopleInduction Therapy of PTX+BV Followed by Atezolizumab+Nab-PTX for PD-L1+ TNBC
- Where
- Koto-ku, 3-8-31
- Age
- 18 years and over
- People
- 106
- Run by
- Japan Breast Cancer Research Group
See details and how to joinNCT06793553